Baldwin Brothers Inc. MA grew its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 33.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,084 shares of the biopharmaceutical company’s stock after acquiring an additional 2,036 shares during the quarter. Baldwin Brothers Inc. MA’s holdings in Regeneron Pharmaceuticals were worth $4,525,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Endurance Wealth Management Inc. increased its stake in Regeneron Pharmaceuticals by 56.3% during the second quarter. Endurance Wealth Management Inc. now owns 50 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 18 shares during the last quarter. San Francisco Sentry Investment Group CA grew its stake in shares of Regeneron Pharmaceuticals by 460.0% in the second quarter. San Francisco Sentry Investment Group CA now owns 56 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 46 shares in the last quarter. Kistler Tiffany Companies LLC grew its stake in shares of Regeneron Pharmaceuticals by 51.3% in the second quarter. Kistler Tiffany Companies LLC now owns 59 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 20 shares in the last quarter. Farmers & Merchants Investments Inc. grew its stake in shares of Regeneron Pharmaceuticals by 64.9% in the second quarter. Farmers & Merchants Investments Inc. now owns 61 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 24 shares in the last quarter. Finally, Larson Financial Group LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $34,000. Institutional investors own 85.89% of the company’s stock.
In related news, VP Christopher R. Fenimore sold 3,709 shares of the firm’s stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $642.04, for a total value of $2,381,326.36. Following the sale, the vice president now owns 25,277 shares of the company’s stock, valued at approximately $16,228,845.08. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $641.93, for a total value of $64,193.00. Following the completion of the sale, the director now directly owns 28,640 shares in the company, valued at approximately $18,384,875.20. The disclosure for this sale can be found here. In the last three months, insiders sold 168,923 shares of company stock worth $101,670,609. Company insiders own 11.28% of the company’s stock.
Shares of NASDAQ REGN traded up $14.56 during mid-day trading on Friday, hitting $599.74. The company had a trading volume of 1,169,004 shares, compared to its average volume of 1,162,364. The stock has a market cap of $63.81 billion, a price-to-earnings ratio of 23.22, a PEG ratio of 1.43 and a beta of 0.50. Regeneron Pharmaceuticals Inc has a 12 month low of $294.86 and a 12 month high of $664.64. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.12 and a quick ratio of 1.68. The firm’s 50 day simple moving average is $578.51 and its two-hundred day simple moving average is $585.04.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $1.57. The business had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.74 billion. Regeneron Pharmaceuticals had a return on equity of 26.71% and a net margin of 37.30%. The business’s revenue was up 23.7% on a year-over-year basis. During the same quarter last year, the business posted $6.02 EPS. Equities analysts forecast that Regeneron Pharmaceuticals Inc will post 28.16 earnings per share for the current year.
A number of equities research analysts have recently issued reports on REGN shares. BidaskClub lowered Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 26th. Benchmark lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 20th. SVB Leerink increased their target price on Regeneron Pharmaceuticals from $629.00 to $650.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Piper Sandler increased their target price on Regeneron Pharmaceuticals from $630.00 to $675.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Finally, Goldman Sachs Group increased their price target on Regeneron Pharmaceuticals from $700.00 to $800.00 in a report on Wednesday, August 5th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $611.64.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
See Also: Trade War
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.